Polycythemia Vera (PV) is a rare hematological malignancy estimated to affect approximately 50 thousand patients in the United States. Based on patient’s age and prior clinical history patients…
The U.S. glaucoma market has seen notable advances in the treatment of OAG following the launches of numerous innovative drugs over the past two years, including Bausch + Lomb’s Vyzulta and…
Trigeminal neuralgia (TGN) is a rare and painful disorder, usually triggered by innocuous stimuli, resulting in paroxysmal neuropathic facial pain in the regions served by the trigeminal nerve…
With more than a dozen disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS), the treatment journey for MS patients is varied and complex. To date, the MS market has…
Glomerulonephritis (GN) is a broad term covering various conditions involving injury and inflammation of the glomerulus, which plays an important role in the filtration of blood in the kidney. As…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States and the first targeted oral therapy to launch for the moderate to severe UC…
KEY BENEFITS AND USESPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Trigeminal neuralgia (TN) is a rare and painful disorder, usually triggered by innocuous stimuli, resulting in paroxysmal neuropathic facial pain in the regions served by the trigeminal nerve…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma patient populations covering 171 countries and more than…
Clarivate Epidemiology’s coverage of urothelial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of urothelial cancer for…
MARKET OUTLOOK Multiple Sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence in the country. Two approved…
Market OutlookThe migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen/Novartis’s…
Hormonal therapies have dominated the treatment of prostate cancer for the past decade. Zytiga (Janssen, generics) and Xtandi (Medivation / Astellas Pharma), initially approved for metastatic…
The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…